{
    "root": "9d401e54-d4f5-43ba-b898-dd08fc3c7bfa",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gabapentin",
    "value": "20250501",
    "ingredients": [
        {
            "name": "GABAPENTIN",
            "code": "6CW7F3G59X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_42797"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "gabapentin indicated : \u2022 management postherpetic neuralgia adults \u2022adjunctive therapy treatment partial onset seizures , without secondary generalization , adults pediatric patients 3 years older epilepsy",
        "doid_entities": [
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 postherpetic neuralgia ( 2.1 ) dose titrated needed dose 1,800 mg/day day 1 : single 300 mg dose day 2 : 600 mg/day ( i.e . , 300 mg two times day ) day 3 : 900 mg/day ( i.e . , 300 mg three times day ) \u2022 epilepsy partial onset seizures ( 2.2 ) patients 12 years age older : starting dose 300 mg three times daily ; may titrated 600 mg three times daily patients 3 11 years age : starting dose range 10 15 mg/kg/day , given three divided doses ; recommended dose patients 3 4 years age 40 mg/kg/day , given three divided doses ; recommended dose patients 5 11 years age 25 35 mg/kg/day , given three divided doses . recommended dose reached upward titration period approximately 3 days \u2022 dose adjusted patients reduced renal function ( 2.3 , 2.4 )",
        "doid_entities": [
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "gabapentin capsules , usp supplied follows : 100 mg : capsules , grey `` 100 mg `` imprinted white body grey `` oe b56 `` white cap . content white off-white powder . bottles 30 : ndc 82804-226-30",
    "adverseReactions": "gabapentin contraindicated patients demonstrated hypersensitivity ingredients .",
    "indications_original": "Gabapentin is indicated for:\n                  \n                     \n                        \u2022\n                        Management of postherpetic neuralgia in adults\n                     \n                     \n                        \u2022Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy",
    "contraindications_original": "\u2022 Postherpetic Neuralgia ( 2.1 ) o Dose can be titrated up as needed to a dose of 1,800 mg/day o Day 1: Single 300 mg dose o Day 2: 600 mg/day (i.e., 300 mg two times a day) o Day 3: 900 mg/day (i.e., 300 mg three times a day) \u2022 Epilepsy with Partial Onset Seizures ( 2.2 ) o Patients 12 years of age and older: starting dose is 300 mg three times daily; may be titrated up to 600 mg three times daily o Patients 3 to 11 years of age: starting dose range is 10 to 15 mg/kg/day, given in three divided doses; recommended dose in patients 3 to 4 years of age is 40 mg/kg/day, given in three divided doses; the recommended dose in patients 5 to 11 years of age is 25 to 35 mg/kg/day, given in three divided doses. The recommended dose is reached by upward titration over a period of approximately 3 days \u2022 Dose should be adjusted in patients with reduced renal function ( 2.3 , 2.4 )",
    "warningsAndPrecautions_original": "Gabapentin capsules, USP are supplied as follows:\n                  100 mg: Capsules, with grey \"100 mg\" imprinted on the white body and grey \"OE B56\" on the white cap. The content is white or off-white powder.\n                  \n                     \n                        \u00a0Bottles of 30: NDC 82804-226-30",
    "adverseReactions_original": "Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.",
    "drug": [
        {
            "name": "Gabapentin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_42797"
        }
    ]
}